Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Aims/hypothesis We assessed the effects of vildagliptin, a novel dipeptidyl peptidase IV inhibitor, on postprandial lipid and lipoprotein metabolism in patients with type 2 diabetes.Subjects, materials and methods This was a single-centre, randomised, double-blind study in drug-naive patients with type 2 diabetes. Patients received vildagliptin (50 mg twice daily, n=15) or placebo (n=16) for 4 weeks. Triglyceride, cholesterol, lipoprotein, glucose, insulin, glucagon and glucagon-like peptide-1 (GLP-1) responses to a fat-rich mixed meal were determined for 8 h postprandially before and after 4 weeks of treatment.Results Relative to placebo, 4 weeks of treatment with vildagliptin decreased the AUC(0-8h) for total trigyceride by 22+/-11% (p=0.037), the incremental AUC(0-8h) (IAUC(0-8h)) for total triglyceride by 85+/-47% (p=0.065), the AUC(0-8h) for chylomicron triglyceride by 65+/-19% (p=0.001) and the IAUC(0-8h) for chylomicron triglyceride by 91+/-28% (p=0.002). This was associated with a decrease in chylomicron apolipoprotein B-48 (AUC(0-8h), -1.0+/-0.5 mg l(-1) h, p=0.037) and chylomicron cholesterol (AUC(0-8h), -0.14+/-0.07 mmol l(-1) h, p=0.046). Consistent with previous studies, 4 weeks of treatment with vildagliptin also increased intact GLP-1, suppressed inappropriate glucagon secretion, decreased fasting and postprandial glucose, and decreased HbA(1c) from a baseline of 6.7% (change, -0.4+/-0.1%, p<0.001), all relative to placebo.Conclusions/interpretation Treatment with vildagliptin for 4 weeks improves postprandial plasma triglyceride and apolipoprotein B-48-containing triglyceride-rich lipoprotein particle metabolism after a fat-rich meal. The mechanisms underlying the effects of this dipeptidyl peptidase IV inhibitor on postprandial lipid metabolism remain to be explored.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to the glucose-lowering actions, GLP-1RA based therapies have been reported to improve both fasting and postprandial lipid profiles in patients with T2D, in particular triglyceride concentrations [104,147,153,176,177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [177]
Experimental — accuracy not yet measuredIn the citing paper
“Additionally, a four-week treatment with DPP-4 inhibitor vildagliptin was also found to induce reductions in the postprandial TG and apolipoprotein B-48 containing TG-rich lipoprotein particle metabolism after a fat meal [177].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsuda, M., & DeFronzo, R. A. (1999) · Diabetes Care · doi:10.2337/diacare.22.9.1462 · Cited by 5,621
Diabetic dyslipidaemia: from basic research to clinical practice*
Taskinen, M.-R. (2003) · Diabetologia · doi:10.1007/s00125-003-1111-y · Cited by 888
Self-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Ahrén, B., Landin-Olsson, M., Jansson, P.-A., Svensson, M., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710
Self-citationOverproduction of large VLDL particles is driven by increased liver fat content in man
Adiels, M., Taskinen, M.-R., Packard, C., Caslake, M. J., Soro-Paavonen, A., Westerbacka, J., Vehkavaara, S., Häkkinen, A., Olofsson, S.-O., Yki-Järvinen, H., et al. (2006) · Diabetologia · doi:10.1007/s00125-005-0125-z · Cited by 690
Self-citationAhrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Self-citationType 2 Diabetes as a “Coronary Heart Disease Equivalent”
Juutilainen, A., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (2005) · Diabetes Care · doi:10.2337/diacare.28.12.2901 · Cited by 452
Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2460 · Cited by 361
Self-citationMaggs, D. G., Buchanan, T. A., Burant, C. F., Cline, G., Gumbiner, B., Hsueh, W. A., Inzucchi, S., Kelley, D., Nolan, J., Olefsky, J. M., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00002 · Cited by 286
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276 · cited 3×
“This situation contrasts with the recent finding in healthy volunteers that exogenous GLP1 infusion (which increased plasma levels >10-fold) eliminated the postprandial increase in TGs [27].”
ResultInfluential
Cited by
Pharmacology, Physiology, and Mechanisms of Action of Dipeptidyl Peptidase-4 Inhibitors
Mulvihill, E. E., & Drucker, D. J. (2014) · Endocrine Reviews · doi:10.1210/er.2014-1035 · Cited by 609
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
O’Keefe, J. H., & Bell, D. S. H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.03.107 · Cited by 538
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
A clinical perspective of obesity, metabolic syndrome and cardiovascular disease
Han, T. S., & Lean, M. E. (2016) · JRSM Cardiovascular Disease · doi:10.1177/2048004016633371 · Cited by 500
Schofield, J. D., Liu, Y., Rao-Balakrishna, P., Malik, R. A., & Soran, H. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0167-x · Cited by 417
Dunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Self-citationHsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2010) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 275
Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes
Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., & Schweizer, A. (2007) · Diabetes Care · doi:10.2337/dc06-1815 · Cited by 270
Self-citationRosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. ‐., Cressier, F., Couturier, A., & Dejager, S. (2007) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00698.x · Cited by 255
Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
Ferrannini, E., & DeFronzo, R. A. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv239 · Cited by 258
Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Schweizer, A., Couturier, A., Foley, J. E., & Dejager, S. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02191.x · Cited by 240
Self-citationDicker, D. (2011) · Diabetes Care · doi:10.2337/dc11-s229 · Cited by 229
Green, B. D., Flatt, P. R., & Bailey, C. J. (2006) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2006.024 · Cited by 223
“There is preliminary evidence that vildagliptin (100 mg/day) can reduce the post-prandial triglyceride excursion after a fat-rich meal.(45) During longer-term studies vildagliptin has shown greater and sustained reductions of HbA1C.”
BackgroundPharmacology of Dipeptidyl Peptidase-4 Inhibitors: Similarities and Differences
Baetta, R., & Corsini, A. (2011) · Drugs · doi:10.2165/11591400-000000000-00000 · Cited by 209
Ahrén, B. (2007) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2007.07.005 · Cited by 204
Dipeptidyl Peptidase-4 Inhibitors
Ahrén, B. (2007) · Diabetes Care · doi:10.2337/dc07-0233 · Cited by 203
Verspohl, E. J. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.06.002 · Cited by 196
Hayashi, T., Fukui, T., Nakanishi, N., Yamamoto, S., Tomoyasu, M., Osamura, A., Ohara, M., Yamamoto, T., Ito, Y., & Hirano, T. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0491-5 · Cited by 196
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes
Pratley, R. E., & Salsali, A. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x162746 · Cited by 195
New insights into the regulation of chylomicron production
Dash, S., Xiao, C., Morgantini, C., & Lewis, G. F. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034338 · Cited by 194
Incretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
“This is also indicated by the fact that DPP-4 inhibitors reduce postprandial triacylglycerol and apoB48 responses, although they only double the concentrations of intact, biologically active GLP-1 [53, 54].”
BackgroundZhong, J., Maiseyeu, A., Davis, S. N., & Rajagopalan, S. (2015) · Circulation Research · doi:10.1161/circresaha.116.305665 · Cited by 189
Ahrén, B., Schweizer, A., Dejager, S., Dunning, B. E., Nilsson, P. M., Persson, M., & Foley, J. E. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2152 · Cited by 183
Self-citationPostprandial hypertriglyceridemia as a coronary risk factor
Borén, J., Matikainen, N., Adiels, M., & Taskinen, M.-R. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.01.015 · Cited by 182
Self-citationChan, S. M. H., Selemidis, S., Bozinovski, S., & Vlahos, R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.013 · Cited by 177
Cardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
Schwartz, E. A., Koska, J., Mullin, M. P., Syoufi, I., Schwenke, D. C., & Reaven, P. D. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.028 · Cited by 173
Mechanisms of action of the dipeptidyl peptidase‐4 inhibitor vildagliptin in humans
Ahrén, B., Schweizer, A., Dejager, S., Villhauer, E. B., Dunning, B. E., & Foley, J. E. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01414.x · Cited by 171
Self-citationRecent advances in pharmacotherapy for hypertriglyceridemia
Sahebkar, A., Chew, G. T., & Watts, G. F. (2014) · Progress in Lipid Research · doi:10.1016/j.plipres.2014.07.002 · Cited by 164
Pan, C., Yang, W., Barona, J. P., Wang, Y., Niggli, M., Mohideen, P., Wang, Y., & Foley, J. E. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02391.x · Cited by 165
Self-citationXiao, C., Bandsma, R. H. J., Dash, S., Szeto, L., & Lewis, G. F. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.246207 · Cited by 164
Flock, G., Baggio, L. L., Longuet, C., & Drucker, D. J. (2007) · Diabetes · doi:10.2337/db07-0697 · Cited by 164
Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes
Tremblay, A. J., Lamarche, B., Deacon, C. F., Weisnagel, S. J., & Couture, P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01362.x · Cited by 160
The Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism
Yu, Y., Raka, F., & Adeli, K. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122227 · Cited by 160
Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
Golightly, L. K., Drayna, C. C., & McDermott, M. T. (2012) · Clinical Pharmacokinetics · doi:10.1007/bf03261927 · Cited by 158
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Saini, K., Sharma, S., & Khan, Y. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1130625 · Cited by 208
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
Postprandial Hyperlipidemia and Remnant Lipoproteins
Masuda, D., & Yamashita, S. (2017) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16003 · Cited by 145
Hermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143
Glucagon‐like peptide‐1‐based therapies and cardiovascular disease: looking beyond glycaemic control
Anagnostis, P., Athyros, V. G., Adamidou, F., Panagiotou, A., Kita, M., Karagiannis, A., & Mikhailidis, D. P. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01345.x · Cited by 141
Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes
Kishimoto, M. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s35682 · Cited by 160
Intestinal lipoprotein overproduction in insulin-resistant states
Adeli, K., & Lewis, G. F. (2008) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3282ffaf82 · Cited by 130
Matikainen, N., Söderlund, S., Björnson, E., Pietiläinen, K., Hakkarainen, A., Lundbom, N., Taskinen, M., & Borén, J. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13487 · Cited by 129
“Lipoprotein fractions (chylomicrons [Sf > 400]; large VLDL1 particles [Sf 60-400] and smaller VLDL2 particles [Sf 20-60]) from blood samples drawn before and during the fat-rich mixed meal test were separated by density gradient ultracentrifugation.(29) Triglyceride and cholesterol concentrations in total plasma and l…”
MethodSelf-citationEffect of Vildagliptin on Hepatic Steatosis
Macauley, M., Hollingsworth, K. G., Smith, F. E., Thelwall, P. E., Al-Mrabeh, A., Schweizer, A., Foley, J. E., & Taylor, R. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3794 · Cited by 128
Self-citationGut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 127
New Drugs for Type 2 Diabetes Mellitus: What is their Place in Therapy?
Krentz, A. J., Patel, M., & Bailey, C. J. (2008) · Drugs · doi:10.2165/00003495-200868150-00005 · Cited by 142
GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production
Hein, G. J., Baker, C., Hsieh, J., Farr, S., & Adeli, K. (2013) · Diabetes · doi:10.2337/db12-0202 · Cited by 121
Vildagliptin: A Review of Its Use in Type 2 Diabetes Mellitus
Keating, G. M. (2014) · Drugs · doi:10.1007/s40265-014-0199-3 · Cited by 126
Scherbaum, W. A., Schweizer, A., Mari, A., Nilsson, P. M., Lalanne, G., Jauffret, S., & Foley, J. E. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00850.x · Cited by 120
Self-citationWeight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experience
Foley (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s10952 · Cited by 119
GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
Yin, M., Silljé, H. H., Meissner, M., van Gilst, W. H., & de Boer, R. A. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-85 · Cited by 118
Oral antidiabetic agents in type 2 diabetes
Levetan, C. S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x178766 · Cited by 127
Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins
Ansar, S., Koska, J., & Reaven, P. D. (2011) · Cardiovascular Diabetology · doi:10.1186/1475-2840-10-61 · Cited by 112
Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system
Aroor, A. R., Sowers, J. R., Jia, G., & DeMarco, V. G. (2014) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00209.2014 · Cited by 111
Scheen, A. J. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.642866 · Cited by 111
Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors
Pratley, R. E., & Gilbert, M. (2008) · The Review of Diabetic Studies · doi:10.1900/rds.2008.5.73 · Cited by 111
Boschmann, M., Engeli, S., Dobberstein, K., Budziarek, P., Strauss, A., Boehnke, J., Sweep, F. C. G. J., Luft, F. C., He, Y., Foley, J. E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1400 · Cited by 110
Self-citationÅhrén, B. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.003 · Cited by 124
Dipeptidyl peptidase‐IV inhibitors: a major new class of oral antidiabetic drug
IDRIS, I. R., & Donnelly, R. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00705.x · Cited by 124
Amerindian-specific regions under positive selection harbour new lipid variants in Latinos
Ko, A., Cantor, R. M., Weissglas‐Volkov, D., Nikkola, E., Reddy, P. M. V. L., Sinsheimer, J. S., Paşaniuc, B., Brown, R., Alvarez, M., Rodríguez, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms4983 · Cited by 116
Self-citationHsieh, J., Hayashi, A. A., Webb, J. P., & Adeli, K. (2008) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2008.05.011 · Cited by 104
Parlevliet, E. T., Wang, Y., Geerling, J. J., Schröder-Van der Elst, J. P., Picha, K., O'Neil, K., Stojanovic-Susulic, V., Ort, T., Havekes, L. M., Romijn, J. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049152 · Cited by 97
“Third, GLP-1 receptor agonism by exendin-4 or the DPP-4 inhibitor sitagliptin reduces the intestinal production of chylomicron-TG and apoB in hamsters [35], and the DPP-4 inhibitor vildagliptin reduces postprandial chylomicron-TG and apoB in T2DM patients [36].”
BackgroundSchernthaner, G., Barnett, A. H., Betteridge, D. J., Carmena, R., Ceriello, A., Charbonnel, B., Hanefeld, M., Lehmann, R., Malecki, M. T., Nesto, R., et al. (2010) · Diabetologia · doi:10.1007/s00125-010-1702-3 · Cited by 97
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
Åhrén, B. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802584126 · Cited by 102
Cardiovascular effects of the DPP-4 inhibitors
Jose, T., & Inzucchi, S. E. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111436236 · Cited by 93
Apaijai, N., Pintana, H., Chattipakorn, S. C., & Chattipakorn, N. (2012) · Endocrinology · doi:10.1210/en.2012-1262 · Cited by 91
Eliasson, B., Möller-Goede, D. L., Eeg‐Olofsson, K., Wilson, C., Cederholm, J., Fleck, P. R., Diamant, M., Taskinen, M., & Smith, U. (2012) · Diabetologia · doi:10.1007/s00125-011-2447-3 · Cited by 95
Self-citationDrug-Induced Hypoglycaemia: An Update
Salem, C. B., Fathallah, N., Hmouda, H., & Bouraoui, K. (2010) · Drug Safety · doi:10.2165/11538290-000000000-00000 · Cited by 97
Vildagliptin: A Review of its Use in Type 2 Diabetes Mellitus
Keating, G. M. (2010) · Drugs · doi:10.2165/11206370-000000000-00000 · Cited by 107
Rizzo, M., Rizvi, A. A., Spinas, G. A., Rini, G. B., & Berneis, K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241633 · Cited by 83
DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
Deacon, C. (2008) · Frontiers in Bioscience · doi:10.2741/2799 · Cited by 80
Cardiovascular Effects of Dipeptidyl Peptidase-4 Inhibitors: From Risk Factors to Clinical Outcomes
Scheen, A. J. (2013) · Postgraduate Medicine · doi:10.3810/pgm.2013.05.2659 · Cited by 82
Consensus statement on management of dyslipidemia in Indian subjects
Chandra, K. S., Bansal, M., Nair, T., Iyengar, S. S., Gupta, R., Manchanda, S. C., Mohanan, P. P., Rao, V. D., Manjunath, C. N., Sawhney, J. P. S., et al. (2014) · Indian Heart Journal · doi:10.1016/j.ihj.2014.12.001 · Cited by 102
Regulation of chylomicron production in humans
Xiao, C., & Lewis, G. F. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.09.019 · Cited by 92
Noda, Y., Miyoshi, T., Oe, H., Ohno, Y., Nakamura, K., Toh, N., Kohno, K., Morita, H., Kusano, K., & Ito, H. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-8 · Cited by 78
Postprandial Dysmetabolism: the Missing Link Between Diabetes and Cardiovascular Events?
Bell, D. S. H., O’Keefe, J. H., & Jellinger, P. S. (2008) · Endocrine Practice · doi:10.4158/ep.14.1.112 · Cited by 83
Song, X., Jia, H., Jiang, Y., Wang, L., Zhang, Y., Mu, Y., & Liu, Y. (2015) · Scientific Reports · doi:10.1038/srep10202 · Cited by 76
Schweizer, A. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s2503 · Cited by 92
Self-citationDipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus
Rosenstock, J., & Zinman, B. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e3280a02f65 · Cited by 81
Xiao, C., Dash, S., Morgantini, C., Patterson, B. W., & Lewis, G. F. (2014) · Diabetes · doi:10.2337/db13-1654 · Cited by 72
Effect of vildagliptin and pravastatin combination on cholesterol efflux in adipocytes
Mostafa, A. M., Hamdy, N. Μ., Abdel‐Rahman, S. Z., & EL-Mesallamy, H. O. (2016) · IUBMB Life · doi:10.1002/iub.1510 · Cited by 85
Moritoh, Y., Takeuchi, K., Asakawa, T., Kataoka, O., & Odaka, H. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.04.018 · Cited by 79
Åhrén, B., & Foley, J. E. (2016) · Diabetologia · doi:10.1007/s00125-016-3899-2 · Cited by 82
Self-citationCarnevale, R., Loffredo, L., Ben, M. D., Angelico, F., Nocella, C., Petruccioli, A., Bartimoccia, S., Monticolo, R., Cava, E., & Violi, F. (2016) · Clinical Nutrition · doi:10.1016/j.clnu.2016.05.016 · Cited by 74
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
The islet enhancer vildagliptin: mechanisms of improved glucose metabolism
Åhrén, B., & Foley, J. E. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01685.x · Cited by 70
Self-citationRosenblit, P. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0412-7 · Cited by 75
Vildagliptin: a new oral treatment for type 2 diabetes mellitus
Mathieu, C. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3005 · Cited by 62
Farr, S., Baker, C., Naples, M., Taher, J., Iqbal, J., Hussain, M., & Adeli, K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.304873 · Cited by 61
Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Seong, J.-M., Choi, N., Shin, J., Chang, Y., Kim, Y.-J., Lee, J., Kim, J. Y., & Park, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124287 · Cited by 61
Xiao, C., Dash, S., Morgantini, C., Adeli, K., & Lewis, G. F. (2015) · Diabetes · doi:10.2337/db14-1706 · Cited by 60
Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials
Coppolino, G., Leporini, C., Rivoli, L., Ursini, F., Paola, E. D. D., Cernaro, V., Arturi, F., Bolignano, D., Russo, E., Sarro, G. D., et al. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.001 · Cited by 64
Dipeptidyl peptidase iv inhibitors and diabetes therapy
McIntosh, C. H. S. (2007) · Frontiers in bioscience · doi:10.2741/2797 · Cited by 63
Xu, F., Corley, E. G., Zacuto, M. J., Conlon, D. A., Pipik, B., Humphrey, G. R., Murry, J. A., & Tschaen, D. M. (2010) · The Journal of Organic Chemistry · doi:10.1021/jo902573q · Cited by 61
New and emerging regulators of intestinal lipoprotein secretion
Xiao, C., Dash, S., Morgantini, C., & Lewis, G. F. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.12.047 · Cited by 62
Metadata
- Authors
- Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R.
- Affiliations
- Helsinki University Hospital (FI)
- Novartis (Switzerland) (CH)
- Corresponding author
- Taskinen, M.-R.
- Venue
- Diabetologia
- Published
- 2006-07-01
- Volume
- 49
- Issue
- 9
- Pages
- 2049-2057
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2152978153
- Cited by
- 336
- References
- 29
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 8 · 2023: 2 · 2022: 8 · 2021: 5 · 2020: 13 · 2019: 11 · 2018: 10 · 2017: 15 · 2016: 24 · 2015: 23 · 2014: 34 · 2013: 38 · 2012: 29
- FWCI
- 15.51
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Työväentutkimus Vuosikirja (submittedVersion, other-oa)
- Funders
- Novartis Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- DPP-4 inhibitors, type 2 diabetes, postprandial lipemia, triglyceride-rich lipoproteins, chylomicrons, apolipoprotein B-48, glucagon-like peptide-1, glucagon secretion, postprandial lipoprotein metabolism
- MeSH terms
- Vildagliptin, Adamantane, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Glucagon, Humans, Insulin, Intestinal Mucosa, Intestines, Lipids, Lipoproteins, Male, Middle Aged, Nitriles, Pyrrolidines, Time Factors, Triglycerides, Treatment Outcome, Postprandial Period, Glucagon-Like Peptide 1, Apolipoprotein B-48, Dipeptidyl-Peptidase IV Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.